Spelling suggestions: "subject:"drugdosage forma."" "subject:"arhysosage forma.""
11 |
The comparative bioavailability and in vitro assessment of solid oral dosage forms of paracetamolBraae, Karen 02 April 2013 (has links)
The dissolution profiles of eight lots of paracetamol tablets representing seven different tablet brands are determined in a USP rotating basket assembly and a stationary basket-rotating paddle apparatus. The in vitro data are expressed in terms of dissolution parameters and inter-tablet differences are assessed statistically using analysis of variance (ANOVA) and the Scheffe test. Highly significant differences are observed between a number of the tablets at the 95% confidence level. Representative tablets from the dissolution rate study and a control dose of paracetamol dissolved in water are subsequently investigated in a 4 x 4 latin square design bioavailability trial. Serum and urine samples are collected and assayed for paracetamol alone (serum) and together with its metabolites (urine) by means of high pressure liquid chromatography. The in vivo data are expressed in terms of bioavailability parameters and differences between the test doses are assessed by means of ANOVA. No significant differences are observed between the dosage forms at the 95% confidence level.
|
12 |
Comparative bioavailability and ranking of topical corticosteroid formulationsMeyer, Eric January 1985 (has links)
Numerous experiments in recent years have indicated differences in the bioavailability of corticosteroids from seemingly identical topical dosage forms. The human blanching assay was utilized in this study to assess the comparative blanching activities of various locally manufactured proprietary corticosteroid preparations. The first experiment was performed to assess the relative blanching activities of six semi - solid preparations containing the same concentration of betamethasone 17-valerate. The preparations used were Betnovate cream and ointment, Persivate cream and ointment and Celestoderm-V cream and ointment. This was followed, in the second experiment, by the investigation of the blanching activities of two lotions containing betamethasone 17-valerate (Betnovate and Celestoderm-V) and a lotion containing betamethasone 17,21- dipropionate (Diprosone). The third experiment involved a study of six semi-solid proprietary corticosteroid-containing formulations, viz. Dermovate (clobetasol propionate) cream and ointment, Betnovate (betamethasone 17-valerate) cream and ointment and Eumovate (clobetasone butyrate) cream and ointment. This investigation was prompted by claims in advertisements in the medical media that Dermovate is therapeutically more efficacious than Betnovate which is more efficacious than Eumovate. The penultimate experiment in this study served the purpose of finding a corticosteroid-containing preparation that falls into the moderately potent group of corticosteroid formulations, as described in the United Kingdom MIMS. This preparation was used in the final experiment which was undertaken to ascertain the potency category of Florone (diflorasone diacetate) cream and ointment.
|
13 |
Development, assessment and optimisation of oral famciclovir formulations for paediatric useMagnus, Laura January 2012 (has links)
Many Active Pharmaceutical Ingredients (API) such as the antiviral agent famciclovir (FCV) are required for paediatric treatment but are not commercially available in age-appropriate dosage forms. It is common practice to prepare oral liquid dosage forms using commercially available tablets, capsules or powdered API and then dispersing or dissolving the crushed and/or powdered materials in a vehicle that the patient can swallow. Vehicles that are commonly used for this purpose include methylcellulose, syrup or combinations of these carriers where possible or commercially available suspending agents such as Ora-Sweet®, if available, can be used. However, several critical factors are overlooked when manufacturing extemporaneous formulations including, but not limited to, physical and chemical properties of the API, excipients, compatibility, stability and bioavailability issues. A stability-indicating High Performance Liquid Chromatography (HPLC) method for the analysis of FCV was developed and validated according to the International Conference on Harmonization (ICH) guidelines. The method is sensitive, selective, precise, accurate and linear over the concentration range 2-120 μg/ml. The stability of 25 mg/ml FCV formulations was assessed in vehicles manufactured from syrup simplex, hydroxypropyl methylcellulose (HPMC), Ora-Sweet® and an aqueous buffer (pH 6) following storage at 25 °C/60% RH and 40 °C/75% RH over six (6) to eight (8) weeks. The shelf life of the products was calculated as the longest period of storage for approximately 90% of the added FCV to be recovered. Formulations were manufactured using syrup simplex or HPMC with methylparaben and propylparaben individually or in combination and with sodium metabisulphite, ascorbic acid or citric acid as antioxidants. The resultant products were subject to quality control analysis for API content, viscosity, pH and appearance and the resultant data were subject to statistical analysis. The degradation rates were calculated for each product and a degradation profile plotted. The degradation rates of FCV in extemporaneous formulations were compared to those of FCV manufactured using a commercially available suspending agent and a buffered vehicle. FCV undergoes major degradation in the presence of sucrose, as observed for formulations in which the vehicle was syrup and Ora-Sweet®. FCV was found to be most stable when dissolved/dispersed in an HPMC vehicle incorporating sodium metabisulphite and a combination of parabens. The formulation that exhibited the maximum stability was manufactured using an aqueous solution buffered to pH 6. Due to the enhanced stability of FCV when added to a buffered vehicle a formulation in which an HPMC vehicle buffered to pH 6 with sodium metabisulphite, methylparaben and propylparaben was selected for optimisation using a Central Composite Design approach (CCD). In this way it was possible to establish a relationship between input variables such as pH, % w/v HPMC, % w/v antioxidant and % w/v preservative and the responses selected for monitoring by means of response surface modelling. A quadratic model was found to be the most appropriate to describe the relationship between input and output variables. Thirty batches of product were randomly manufactured according to the CCD and analysed to establish the stability in respect of viscosity, pH and the amount of FCV remaining following storage and the data were fitted to models using Design-Expert® software. A correlation between input variables and the responses was best described by a quadratic polynomial model. Analysis of Variance indicated that the response surface models were significant (P-value < 0.0001). The pH to which a FCV formulation was buffered was the most significant factor to effect the % drug content and the ultimate pH of the formulation, while the % w/v HPMC had the most significant effect on the viscosity of the product. The optimum composition for the manufacture of an oral liquid FCV formulation was predicted using the optimisation function of the Design-Expert® software. A low % error of prediction was established, indicating that the model is robust and that RSM is an appropriate formulation optimisation tool as it has a high prognostic ability. A liquid FCV formulation was developed, optimised and found to be suitable for its intended purpose. However further optimisation is required in respect of colourants, sweeteners and/or flavourants. The approach followed is useful in ensuring the development of quality products and can be applied in future.
|
14 |
Development and assessment of an oxytocin parenteral dosage form prepared using pluronic ® F127Chaibva, Faith Anesu January 2007 (has links)
No description available.
|
15 |
The design, preparation and evaluation of Artemisia Afra and placebos in tea bag dosage form suitable for use in clinical trials.Dube, Admire January 2006 (has links)
<p>Artemisia Afra, a popular South African traditional herbal medicine is commonly administered as a tea infusion of the leaves. However, clinical trials proving it safety and efficacy are lacking mainly due to the absence of good quality dosage forms and credible placebos for the plant. The objectives of this study were to prepare a standardized preparation of the plant leaves and freeze-dried aqueous extract powder of the leaves, in a tea bag dosage form and to design and prepare credible placebos for these plant materials.</p>
|
16 |
Avaliação de complexos de inclusão e micropartículas poliméricas como alternativas de estabilização do composto antiprotozoário, antibacteriano e antifúngico 2-(2-nitrovinil) furano (G-0) /Ruz Sanjuan, Vivian. January 2019 (has links)
Orientador: Anselmo Gomes de Oliveira / Banca: Rosemeire Cristina Linhari Rodrigues Pietro / Banca: Thalita Pedroni Formariz Pilon / Banca: Clovis Augusto Ribeiro / Banca: Francisco Benedito Teixeira Pessine / Resumo: 2-(2-nitrovinil)furano (G-0) apresenta atividade antiprotozoária, antibacteriana e antifúngica frente a elevado número de patógenos porém, a capacidade de sublimação, baixa velocidade de dissolução em meio aquoso, problemas de compatibilidade com excipientes e fotodegradação, tem limitado sua incorporação em formas farmacêuticas para uso humano e/ou veterinário. O propósito do presente trabalho foi avaliar duas alternativas para a estabilização do candidato a fármaco, através da formação de complexos de inclusão liofilizados (FD) com hidroxipropil-β-ciclodextrina e sulfobutiléter-β-ciclodextrina sódica e utilizando a microencapsulação com etilcelulose pelo método de emulsificação/evaporação do solvente. Uma vez formados e previamente caracterizados, os complexos foram submetidos ao ensaio de estabilidade acelerada a 40°C/75 %HR e ensaios de fotoestabilidade acelerada. A câmara de fotoestabilidade também foi utilizada para confirmar o perfil de degradação dos complexos. Os fotoprodutos foram isolados em coluna analítica e o maioritário foi caracterizado por espectroscopia de RMN. Foi avaliada também a volatilidade do G-0 na forma de complexos comparado com misturas físicas equivalentes através de TGA e CG-HS-FID, complementando assim um estudo desenvolvido anteriormente no modo isotérmico. As propriedades biofarmacêuticas da substância livre e na forma complexada foram estudadas em relação ao comportamento de dissolução em Fluido Vaginal Simulado e a permeação/retenção em muco... (Resumo completo, clicar acesso eletrônico abaixo) / Abstract: 2-(2-nitrovinyl)furan (G-0) has antiprotozoal, antibacterial and antifungal activity against a large number of pathogens, although the sublimation, low dissolution rate in aqueous medium, low compatibility with excipients and photodegradation, have hindered the incorporation in pharmaceutical dosage forms, to use in human and/or veterinary medicine. The aim of this work was to evaluate two alternatives for the stabilization of the drug candidate through freeze-drying inclusion complex formation (FD) with hydroxypropyl-β-cyclodextrin and sulfobutylether-β-cyclodextrin sodium salt and through microencapsulation with ethylcellulose by mean of emulsion/solvent evaporation method. Once the complexes were prepared and fully characterized previously, they were subjected to an accelerated stability study at 40°C/75 %RH, and a photostability assay under forced irradiation conditions. A photostability chamber was also used in order to confirm the degradation profile for the complexes. Photoproducts were isolated in analytical column and the main degradation product was characterized aided by NMR. Drug volatility was also evaluated when G-0 was complexed, and compared with equivalent physical mixtures through TGA and GC-HS-FID. Biopharmaceutical properties of free drug and in the complexes were studied in terms of dissolution rate in Simulated Vaginal Fluid and permeation/retention in bovine vaginal mucosa. Finally, the influence of both complexes on the "in vitro" antifungal activity a... (Complete abstract click electronic access below) / Doutor
|
17 |
Development of graphene oxide-based hydrogel biocomposite with anti-diabetic activity.Owonubi, Shesan John. January 2015 (has links)
M. Tech. Polymer Technology / Type II diabetes afflicts more than 300 million people worldwide. The pursuit for improved targeted drug delivery systems has led to the development of highly improved biomaterials with enhanced biocompatibility and biodegradability properties. Hydrogels are of particular interest for drug delivery applications due to their ability to address targeted drug delivery, in addition to their good biocompatibility, tunable network structure needed to control the diffusion of drugs and their ability to imbibe drugs within their mesh network structure. Hydrogels are promising candidates for advanced anti-diabetic applications. They were prepared by application of free-radical polymerization of acrylamide (AAm) in the presence of partially and thermally reduced graphene oxide (rGO) and wheat protein isolate (WPI). The incorporation of two (or more) different drugs onto a single delivery vehicle and the realization of combination therapy is a challenging, just as it is an important aspect for smart drug delivery. Thus, the development of dual drug delivery systems that can control the release behaviours of each drug is highly pertinent. This project aims to develop a dual drug delivery system with smart polymers, exploiting stimuli responses to be utilized as a carrier vehicle to aid in proffering a cure for diabetes. Also, it aims at proffering a solution to the lingering issue of combination therapy; by comparing the effect of the test drugs individually and in combination as anti-diabetic drugs.
|
18 |
The design, preparation and evaluation of Artemisia Afra and placebos in tea bag dosage form suitable for use in clinical trials.Dube, Admire January 2006 (has links)
<p>Artemisia Afra, a popular South African traditional herbal medicine is commonly administered as a tea infusion of the leaves. However, clinical trials proving it safety and efficacy are lacking mainly due to the absence of good quality dosage forms and credible placebos for the plant. The objectives of this study were to prepare a standardized preparation of the plant leaves and freeze-dried aqueous extract powder of the leaves, in a tea bag dosage form and to design and prepare credible placebos for these plant materials.</p>
|
19 |
Formulation and assessment of monolithic beta blocker sustained release tablets prepared by direct compressionKieser, Leith Faye January 2002 (has links)
Beta blockers are commonly prescribed for the chronic treatment of hypertension, one of the most prolific disease states worldwide. The beta blockers selected for this study include acebutolol hydrochloride, labetalol hydrochloride, metoprolol tartrate oxprenolol hydrochloride and propranolol hydrochloride. All of these compounds have a short elimination half-life, necessitating multiple dose per day regimens and therefore the development of sustained release dosage forms incorporating these agents was considered beneficial in terms of extending the dosing interval, with the aim of improving patient compliance and subsequent therapeutic outcomes. Preformulation studies that were conducted included moisture content analysis by Karl Fischer titration, and DSC, a method used to predict potential interactions between the drugs and tablet excipients. Tablets were manufactured by both wet granulation and direct compression techniques, and the resultant drug release characteristics were evaluated using the USP Apparatus 3(BIO.DIS). A validated isocratic HPLC method, capable of separating the five drug candidates simultaneously, was developed and used for the analysis of drug samples. Tablet quality was assessed using analyses that included the physical assessment of weight, diameter, thickness, hardness and friability, as well as content uniformity of tablets, before and after dissolution testing. Direct compression tablet formulations containing each of the five beta blockers were successfully adapted from a prototype wet granulation matrix tablet containing metoprolol tartrate, and various formulation variables were investigated to establish,their effect on the rate and extent of drug release from these tablets. The grade and quantity of ethylcellulose used in the wet granulation and direct compression formulae influenced the release rate of some drug candidates. In addition, an alternative formulation method, involving freeze-drying of the drug with an ethylcellulose dispersion, was shown to have potential for altering release rates further. Anti-frictional agents, talc and colloidal silicon dioxide, did not affect drug release from these matrices,however, they affected the physical character:istics such as tablet weight and thickness, of the resultant tablets. All of the matrix tablets formulated were shown to release drug according to square root of time kinetics, in a sustained manner over a 22 hour period.
|
20 |
Development and assessment of minocycline sustained release capsule formulationsSachikonye, Tinotenda Chipo Victoria January 2010 (has links)
The use of minocycline for the treatment of a broad range of systemic infections and for severe acne has been associated with vestibular side effects. The severity of side effects may lead to poor adherence to therapy by patients. The use of sustained release formulations of minocycline that display slow dissolution of minocycline following administration may be beneficial in reducing the incidence and severity of side effects. Therefore, sustained release capsule dosage forms containing 100 mg minocycline (base) were manufactured and assessed for use as sustained release oral dosage forms of minocycline. Minocycline sustained release capsules were manufactured based on matrix technologies using hydroxypropylmethyl cellulose (HPMC) and Compritol® as release retarding polymers. The rate and extent of minocycline release from the capsules was evaluated using USP Apparatus 1 and samples were analysed using a validated High Performance Liquid Chromatographic (HPLC) method with ultraviolet (UV) detection. Differences in the rate and extent of minocycline release from formulations manufactured using HPMC or Compritol® were influenced by the concentration of polymer used in the formulations. The rate and extent of minocycline release was faster and greater when low concentrations of polymer were used in formulations. The effect of different excipients on the release pattern(s) of minocycline and particularly their potential to optimise minocycline release from experimental formulations was investigated. The use of diluents such as lactose and microcrystalline cellulose (MCC) revealed that lactose facilitated minocycline release when HPMC was used as the polymer matrix. In contrast, the use of lactose as diluent resulted in slower release of minocycline from Compritol® based formulations. The addition of sodium starch glycolate to HPMC based formulations resulted in slower release of minocycline than when no sodium starch glycolate was used. Compritol® based formulations were observed to release minocycline faster following addition of sodium starch glycolate and Poloxamer 188 to experimental formulations. In vitro dissolution profiles were compared to a target or reference profile using the difference and similarity factors, ƒ1 and ƒ2 , and a one way analysis of variance (ANOVA). In addition, the mechanism of minocycline release was elucidated following fitting of dissolution data to the Korsmeyer-Peppas, Higuchi and Zero order models. Minocycline release kinetics were best described by the Korsmeyer-Peppas model and the values of the release exponent, n (italics), revealed that drug release was a result of the combined effects of minocycline diffusion through matrices and erosion of the matrices. These in vitro dissolution profiles were better fit to the Higuchi model than to the Zero order model. Two formulations that displayed a fit to the Zero order model were identified for further studies as potential dosage forms for sustained release minocycline.
|
Page generated in 0.0544 seconds